Lymph node (LN) status is the most significant prognostic factor for invasive urothelial bladder cancer (UBC); however, the optimal extent of LN dissection (LND) is debated. We assessed circulating matrix metalloproteinase-7 (MMP-7) as a prognostic factor and decision-making marker for the extent of LND. Preoperative serum MMP-7 levels were determined in two independent UBC cohorts (n = 188; n = 68) and in one control cohort (n = 97) by using the ELISA method. A systematic review and meta-analysis on the prognostic role of circulating pretreatment MMP-7 levels were performed. Serum MMP-7 levels were higher in patients compared to controls (p < 0.001) with the highest levels in LN-positive cases. Half of LN-positive UBC patients had low MMP-7 levels, whereas the survival of LN-negative patients with high serum MMP-7 findings was poor. MMP-7 levels were independently associated with poor survival in both cohorts (p = 0.006, p < 0.001). Accordingly, our systematic review of six eligible publications revealed a 2.5-fold higher mortality risk in patients with high MMP-7 levels. In conclusion, preoperative MMP-7 level is a validated and independent prognostic factor in urothelial cancer. It cannot be used to decide between regional or extended LND but may be useful in identifying LN-negative high-risk patients with potentially undetected metastases.
Background/Objectives: Nutritional preparations are used by women with polycystic ovary syndrome (PCOS), but their short-term metabolic effects are uncertain. Methods: MEDLINE, Embase and the Cochrane Library were searched up to 4 December 2025 (PROSPERO: CRD42023424883). Between-group mean differences (MDs) in change from baseline were pooled separately for each intervention–comparator pair (restricted maximum likelihood, modified Hartung–Knapp 95% confidence intervals [CIs]). Risk of bias was assessed with the Cochrane risk-of-bias tool for randomized trials, version 2 (RoB 2) and certainty with GRADE (Grading of Recommendations Assessment, Development and Evaluation). Several analyses were post hoc. Results: Of 40 reports of 38 trials, 28 reports (26 trials) entered the primary analyses. Of 62 pooled estimates, two excluded no difference: 25-hydroxyvitamin D (25(OH)D) increased with vitamin D3 (five trials, 298 participants, MD +15.19 ng/mL, 95% CI 8.36 to 22.02, very low certainty) and homeostatic model assessment of insulin resistance (HOMA-IR) decreased with cinnamon (three trials, 185 participants, MD −1.03, 95% CI −1.97 to −0.09, low certainty), but this was not robust to omitting any single trial. Vitamin D3 did not clearly change fasting insulin or glucose. D-chiro-inositol estimates were highly imprecise. Of 176 graded estimates, 67 were of low and 109 of very low certainty. Conclusions: Apart from the expected rise in 25(OH)D, nutritional preparations showed no robust short-term metabolic effect in PCOS. The evidence does not support ranking preparations or treatment recommendations.